Ixekizumab and Tirzepatide combo Improves PsA Control and Weight Loss, suggests study Dr. Kamal Kant Kohli13 Jan 2026 8:15 PM ISTThe TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis disease control and greater...
This isn't the Durability You Thought You Knew: A Fresh Perspective on Psoriasis Dr. Bhumika Maikhuri24 Dec 2025 10:30 AM ISTIn this short video, Matteo Megna, Associate Professor at the University of Naples Federico II, Naples, Italy, discusses durability as a novel ...
Targeting IL-17A may Modify Risk Factors for Psoriatic Arthritis in Patients with Psoriasis Dr. Bhumika Maikhuri19 Dec 2025 11:00 AM ISTOverviewIn this short video, Dr. Paolo Gisondi, MD, Associate Professor of Dermatology and Venereology at the University of Verona, Italy, discusses...
Real-World Evidence in Psoriatic Arthritis: PRO-SPIRIT Study Dr. Garima Soni25 Nov 2025 11:45 AM ISTIn the video, Dr. Nicola J. Gullick, a Consultant Rheumatologist in Coventry and one of the investigators on the PRO-SPIRIT study, provides an...
Secukinumab Offers Better Psychological Benefits in Psoriasis Treatment: Study Medha Baranwal23 Nov 2025 9:00 PM ISTChina: Researchers have found in a new study that secukinumab and ixekizumab demonstrate comparable clinical efficacy for moderate-to-severe...
Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update Dr. Divya Colin9 Aug 2025 12:30 PM ISTNew Delhi: Eli Lilly and Company (India) Pvt Ltd has secured regulatory clearance from the Subject Expert Committee (SEC) under the Central Drugs...
Submit efficacy data of Indian population: CDSCO Panel Tells Eli Lilly for approval of additional indications of Ixekizumab Dr. Divya Colin9 Oct 2024 6:00 PM ISTNew Delhi: Citing that there is no efficacy data in the Indian population, the Subject Expert Committee (SEC) functional under the Central Drug...
Ixekizumab significantly relieves back pain, morning stiffness and disease activity in psoriatic arthritis Aditi22 Sept 2023 9:00 AM ISTPsoriatic arthritis (PsA) is a chronic inflammatory condition predominantly affecting peripheral joints. The disease has heterogeneous manifestations,...
Ixekizumab safe to use in Pediatric Patients with Moderate to Severe Plaque Psoriasis: JAMA Medical Dialogues Editorial Team30 April 2022 9:00 AM ISTA new study conducted by Amy S. Paller and team showed improvements in patient-reported outcomes and objective measures of full psoriasis skin...
Head-to-head trials reveal higher skin and nail clearance with ixekizumab in psoriasis patients Medha Baranwal15 April 2022 9:00 AM ISTUSA: In five head-to-head trials, treatment with ixekizumab in psoriasis patients was associated with higher rates of simultaneous complete skin and...
Continued ixekizumab therapy better than ixekizumab withdrawal in Psoriatic Arthritis patients MD Bureau2 Feb 2022 9:00 AM ISTThere are several disease-modifying antirheumatic drugs (DMARDs) available to patients with psoriatic arthritis (PsA), including conventional...
First case of Granuloma annulare after ixekizumab administration reported Dr Manoj Kumar Nayak10 Dec 2021 9:00 AM ISTGranuloma annulare post ixekizumab administration- 1 case report Psoriasis is a complex immune mediated disease influenced by multiple genetic...
